u/CoolioBeansTTV · 227d ago3 prior · 67% at 3mo
3 stocks under 9x forward P/E that institutions are quietly loading up on
Viatris trades at 5.5x forward P/E as a specialty pharma/generics turnaround post-Phase 2 restructuring, with 2026 guidance of $14.7B revenue (+3% growth) and $450-550M from new launches. The MR-141 presbyopia drug has an FDA date in October targeting ~90% of US adults over 45, hiring jumped 170% in three months, and major institutions (Vanguard, BlackRock) recently added positions.
At post $13.60Now $18.64+37.0% since postedas of Oct 27, 1:01 PM ET
1d-0.4%
3d-4.3%
1w-3.2%
1m+1.5%
3m+19.1%
6m+21.4%
1y—